Julie Fox

Julie Fox publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Julie Fox sits on this spectrum.

Julie Fox D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Julie Fox sits on this spectrum.

Best Publications

• Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.

  Sheena McCormack;David T. Dunn;Monica Desai;David I. Dolling

  2193
  Citations

• Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

  Alison J Rodger;Valentina Cambiano;Tina Bruun;Pietro Vernazza

  1068
  Citations

• Early and nonreversible decrease of CD161++ /MAIT cells in HIV infection.

  Cormac Cosgrove;James E. Ussher;Andri Rauch;Kathleen Gärtner

  361
  Citations

• Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.

  J Frater;K J Ewer;A Ogbe;M Pace

  232
  Citations

• Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans.

  Kathleen B. Yates;Kathleen B. Yates;Pierre Tonnerre;Pierre Tonnerre;Genevieve E. Martin;Genevieve E. Martin;Ulrike Gerdemann

  215
  Citations

• Reductions in HIV transmission risk behaviour following diagnosis of primary HIV infection: a cohort of high-risk men who have sex with men.

  Julie Fox;Peter J White;Peter J White;Neil Macdonald;Jonathan Weber

  206
  Citations

• Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial.

  Nicholas I. Paton;Ruth L. Goodall;David T. Dunn;Samuel Franzen

  175
  Citations

• Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection.

  Matthias Hoffmann;Matthias Hoffmann;Nikos Pantazis;Genevieve E. Martin;Stephen Hickling

  171
  Citations

• Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

  Jean-Michel Molina;Kathleen Squires;Paul E Sax;Pedro Cahn

  165
  Citations

• Alterations in T and B cell function persist in convalescent COVID-19 patients.

  Halima A Shuwa;Tovah N Shaw;Sean B Knight;Kelly Wemyss

  156
  Citations

• Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial

  Unknown

  155
  Citations

• Exploring Perceived Barriers and Facilitators of PrEP Uptake among Young People in Uganda, Zimbabwe, and South Africa

  Richard Muhumuza;Andrew Sentoogo Ssemata;Ayoub Kakande;Nadia Ahmed

  151
  Citations

• Sexual transmission of HIV-1.

  Julie Fox;Sarah Fidler

  144
  Citations

• Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial

  S Fidler;W Stöhr;M Pace;L Dorrell

  129
  Citations

• Improvement in vitamin D deficiency following antiretroviral regime change: Results from the MONET trial.

  Julie Fox;Barry Peters;Manyu Prakash;Jose Arribas

  123
  Citations

• Ultrasensitive Detection and Phenotyping of CD4+ T Cells with Optimized HLA Class II Tetramer Staining

  Thomas J. Scriba;Marco Purbhoo;Cheryl L. Day;Nicola Robinson

  112
  Citations

• An overview of the relative risks of different sexual behaviours on HIV transmission.

  Olamide Dosekun;Julie Fox

  103
  Citations

• Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial

  Nicholas I Paton;Nicholas I Paton;Wolfgang Stöhr;Alejandro Arenas-Pinto;Martin Fisher

  99
  Citations

• Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.

  José M. Gatell;Lambert Assoumou;Graeme Moyle;Laura Waters

  96
  Citations

• BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022

  Unknown

  90
  Citations